更正：B7-H3 CAR T 细胞清除肝内胆管癌并诱导持久应答
Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.
98.9分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胆道癌免疫治疗进展
英文原题：Advances in immunotherapy for biliary tract cancers.
研究概要
胆道癌（BTC）是一种异质性较强、预后较差的疾病，包括胆囊癌（GBC）、肝内胆管癌（ICC）和肝外胆管癌（ECC）。
中文摘要
胆道癌（BTC）是一种预后较差的异质性疾病，包括胆囊癌（GBC）、肝内胆管癌（ICC）和肝外胆管癌（ECC）。尽管手术目前是治疗BTC的主要方案，但大多数BTC患者确诊时已处于晚期，错失了手术根治的机会。因此，非手术治疗成为晚期BTC的主要干预手段。近年来，免疫治疗已成为多种实体瘤中最有前景的疗法之一，包括免疫检查点抑制剂（ICIs）单药或联合治疗、肿瘤疫苗、溶瘤病毒免疫治疗、过继细胞治疗（ACT）和细胞因子治疗。然而，这些疗法在BTC患者中的临床应用仍然有限。在本综述中，我们重点讨论BTC免疫治疗的最新进展，并更新当前多种不同免疫治疗的临床试验进展。
展开英文摘要原文
Biliary tract cancers (BTC), a heterogeneous disease with poor prognosis, including gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (ICC), and extrahepatic cholangiocarcinoma (ECC). Although surgery is currently the primary regimen to treat BTC, most BTC patients are diagnosed at an advanced stage and miss the opportunity of surgical eradication. As a result, non-surgical therapy serves as the main intervention for advanced BTC. In recent years, immunotherapy has emerged as one of the most promising therapies in a number of solid cancers, and it includes immune checkpoint inhibitors (ICIs) monotherapy or combined therapy, tumor vaccines, oncolytic virus immunotherapy, adoptive cell therapy (ACT), and cytokine therapy. However, these therapies have been practiced in limited clinical settings in patients with BTC. In this review, we focus on the discussion of latest advances of immunotherapy in BTC and update the progress of multiple current clinical trials with different immunotherapies.
论文信息
- 作者
- Zhao Y、Yang M、Feng J、Wang X、Liu Y
- 单位
- Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.China
- 文献类型
- 综述
- 期刊
- Chinese medical journal2024 Mar 5
- 原文标识
- PubMed 37646139 · DOI 10.1097/CM9.0000000000002759